Primary focal glomerulosclerosis nephrotic syndrome in adults;Síndrome nefrótico por glomerulosclerosis focal primaria en el adulto

Nefrologia

Volumn 27, Issue SUPPL.2, 2007, Pages 56-69

  Quereda, C ^a   Ballarin J ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b FUNDACIÓ PUIGVERT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 51249122360     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Mallick N, Secondary focal glomerulosclerosis not due to HIV. Nephrol Dial Transplant 18 (Supl. 6): 4-7, 2003.
2. Kramer H: Obesity and chronic kidney disease. Contrib Nephrol 151: 1-18, 2006.
3. Ferrario F, Rastaldi MP, Pasi A, Secondary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 14 (Supl. 3): 58-67, 1999.
4. Praga M, Morales E, Herrero JC y cols.: Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 33: 52-8, 1999.
5. Dantal J, Baatard R, Hourmant M y cols.: Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis. A one-center study of plasma exchange effects. Transplantation 52: 827-31, 1991.
6. Dantal J, Bigot E, Bogers W y cols.: Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 330: 7-14, 1994.
7. Kemper MJ, Wolf G, Muller-Wiefel DE.: Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 1; 344: 386-7, 2001.
8. Ruf RG, Lichtenberger A, Karle SM y cols.: Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome. J Am Soc Nephrol 15: 722-732, 2004.
9. Tsukaguchi H, Sudhakar A, Le TC y cols.: NPHS2 mutations in late -onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest 110: 1659-1666, 2002.
10. Horinouchi I, Nakazato H, Kawano T y cols.: In situ evaluation of podocin in normal and glomerular diseases. Kidney Int 64 (6): 2092-9, 2003.
11. Weins A, Kenlan P, Hebert S y cols.: Mutational and biological analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol 16: 3694-3701, 2005.
12. Winn M.: Approach to the evaluation of heritable renal disease and update on familial focal segmental glomerulosclerosis. Nephrol Dial Transplant 18: 4-20, 2003.
13. Reiser J, Polu KR, Moller CC y cols.: TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 37: 739-44, 2005.
14. Weber S, Gribouval O, Esquivel EL y cols.: NPHS2 mutaton analysis shows genetic heteogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 66: 571-579, 2004.
15. Kitiyakara C, Eggers P, Kopp JB.: Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Disease 44: 815-825, 2004.
16. Haas M, Meehan SM, Karrison TG, Spargo BH.: Changing etiologies of unexplained adult nephrotic syndromes: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 30: 621-631, 1997.
17. Dragovic D, Rosenstock JL, Wahl SJ y cols.: Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns. Clin Nephrol 63: 1-7, 2005.
18. Cameron JS.: Focal segmental glomerulosclerosis in adults. Nephrol Dial Transplant 18 (Supl. 6): 45-51, 2003.
19. Schena FP, the Iain group of Renal Immunopathology. Survey of the Italian registry of renal biopsies. Frequency of the renal diseases for seven consecutive years. Nephrol Dial Transplant 12: 418-426, 1997.
20. Rychlík I, Jancová E, Tesar V y cols.: Occurrence of renal diseases in the years 1994-2000. Nephrol Dial Transplant 19: 3040-3049, 2004.
21. Beaufils H, Alphonse JC, Guedon J, Legrain M.: Focal glomerulosclerosis: natural history and treatment. A report of 70 cases. Nephron 21: 75-85, 1978.
22. Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG.: The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10: 213-218, 1978.
23. Velosa JA, Holley KE, Torres VE, Offord KP.: Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis. Mayo Clin Proc 58 (9): 568-77, 1983.
24. Korbet SM, Schwartz MM, Lewis EJ.: The prognosis of focal segmental glomerular sclerosis of adulthood. Medicine 65: 304-11, 1986.
25. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM.: Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 25: 534-42, 1995.
26. Stirling CM, Mathieson P, Boulton-Jones JM y cols.: Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM 98 (6): 443-9, 2005.
27. Cattran DC, Rao P.: Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32: 72-9, 1998.
28. Goumenos DS, Tsagalis G, El Nahas AM, Shortland JR, Davlouros P, Vlachojannis JG, Brown CB.: Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a fiveyear follow-up study. Nephron Clin Pract 104: c75-82, 2006.
29. D'Agati VD.: Pathological classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Disease 43: 368-382, 2004.
30. Schwartz MM, Evans J, Bain R, Korbet SM.: Focal segmental glomerulosclerosis: pronostic implications of the cellular lesions. J Am Soc Nephrol 10: 1900-1907, 1999.
31. Howie AJ, Pankhurst T, Sarioglu S, Turhan N, Adu D.: Evolution of nephrotic -associated glomerulosclerosis and relation to the glomerular tip lesion. Kidney Int 67: 987-1001, 2005.
32. Chun MG, Korbet SM, Schwartz MM, Lewis EJ.: Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis and response to therapy of histologic variants. J Am Soc Nephrol 15: 2169-2177, 2004.
33. Stokes MB, Markowitz GS, Lin J, Valeri AM, D'Agti VD.: Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 65: 1690-1702, 2004.
34. Herman ES, Klotman PE.: HIV-associated nephropathy: epidemiology, pathogenesis and treatment. Sem Nephrol 23: 2000-2008, 2003.
35. Tanawattanacharoen S, Falk R, Jennette JC, Kopp JB.: Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis. Am J Kidney Dis 1166-1174, 2000.
36. Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F.: Recurrent focal glomerulosclerosis: natural history and response to therapy: Am J Med 92 (4): 375-383 (= 46), 1992.
37. Banfi G, Colturi C, Montagnino G, Ponticelli C.: The recurrence of focal segmental glomerulosclerosis in kidney transplant patients treated with cyclosporine. Transplantation 50 (4): 594-596, 1990.
38. Akioka K, Okamoto M, Wakabayashi Y, Nobori S, Ogino S, Ushigome H, Uryuhara K, Kaihara S, Yoshimura N.: Long.Term outcome of Renal transplantation in focal glomerulosclerosis. Transplantation Proceedings 38: 2819-2822
39. Kim EM, Striegel J, Kim Y,Matas AJ, Najarian JS, Mauer SM.: Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute refection. Kidney Int 45 (5): 1440-1445, 1994.
40. Stephanian E, Matas AJ, Mauer SM, Chavers B, Nevins T, Kashtan C, Sutherland DE, Gores P, Najarian JS.: Recurrence of disease in patients retransplanted for focal segmental glomerulosclerosis: Transplantation 53: 755-757, 1992.
41. Pinto J, Lacerda G, Cameron JS, Turner DR, Bewick M, Ogg CS.: Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation 32: 83-89, 1981.
42. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz CJ, Roza AM, Vincenti F, George V.: Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 68 (5): 635-641, 1999.
43. Deegens JKJ, Andresdottir M B, Croockewit S, Wetzels JFM.: Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplantation. Transpl Int 17: 151-157, 2004.
44. Pardon A, Audard V, Caillard S, Molin B, Desvaux D, Bentaarit B, Remy P, Sahali D, Roudot-Thoraval F, Lang P, Grimbert P.: Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients: Nephol Dial Transplant 21: 1053-1059, 2006.
45. Shariatmadar S, Noto TA.: Therapeutic Plasma exchange in recurrent focal segmental glomerulosclerosis following transplantation. Journal of Clinical Apheresis 17: 78-83, 2002.
46. Andresdottir MB, Ajubi N, Croockewit S, Assmann KJM, Hilbrands LB, Wetzels JFM.: Recurrent focal glomerulosclerosis: natural course and treatment with plasma exchange. Neprhol Dial Transplant 14: 2650-2656, 1999.
47. Cameron JS, Senguttuvan P, Hartley B, Rigden SP, Chantler C, Koffman G, Williams DG, Ogg CS.: Focal segmental glomerulosclerosis in fifty-nine renal allografts from a single centre; analysis of risk factors for recurrence. Transplant Proc 21: 2117-2118, 1989.
48. Banfi G, Colturi C, Montagnino G, Ponticelli C.: The recurrence of focal and segmental glomerulosclerosis in patients treated with cyclosporine. Transplantation 50: 594-596, 1990.
49. Raafat R, Travis LB, Kalia A, Diven S.: Role of transplant induction therapy on recurrence rate of focal segmental glomerulosclerosis. Pediatr Nephrol 14 (3): 189-194, 2000.
50. Uhlig K, MacLeod A, Craig J, Lau J, Levey AS, Levin A, Moist L, Steinberg E, Walker R, Wanner C, Lameire N, Eknoyan G.: Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from kidney disease: improving global outcomes (KDGIGO). Kidney Int 70 (12), 2006.
51. Quereda C, Ballarín J, Galeano C, García López F, Praga M.: Tratamiento inmunosupresor de la hialinosis segmentaria y focal del adulto: una revisión sistemática. Nefrología 2006 (en prensa)
52. Newman WJ, Tisher CC, McCoy RC y cols.: Focal glomerular sclerosis: contrasting clinical patterns in children and adults. Medicine (Baltimore) 55 (1): 67-8, 1976.
53. Nagai R, Cattran DC, Pei Y.: Steroid therapy and prognosis of focal segmental glomerulosclerosis in the elderly. Clin Nephrol 42 (1): 18-21, 1994.
54. Pei Y.: Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am J Med 82 (5): 938-44, 1987.
55. Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C.: The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 36 (2): 53-9, 1991.
56. Rydel JJ.: Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 25 (4): 534-42, 1995.
57. Ponticelli C, Villa M, Banfi G y cols.: Can prolonged treatment improve the prognosis in adults with focal segmental glomerulo-sclerosis? Am J Kidney Dis 34 (4): 618-25, 1999.
58. Alexopoulus F y cols.: Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Trasplant 15: 1348-1356, 2000.
59. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ.: Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 15 (8): 2169-77, 2004.
60. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC.: Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 16 (4): 1061-1068, 2005.
61. Lim VS, Sibley R, Spargo B.: Adult lipoid nephrosis: clinicopathological correlations. Ann Intern Med 81 (3): 314-20, 1974.
62. Jenis EH, Teichman S, Briggs W y cols.: Focal segmental glomerulosclerosis. Am J Med 57 (5): 695-705, 1974.
63. Saint-Hillier Y, Morel-Maroger L, Woodrow D, Richet G.: Focal and Segmental Hyalinosisis. Adv Nephrol 5: 67-88, 197.
64. Bolton WK, Atuk NO, Sturgill BC, Westervelt FB Jr.: Therapy of the idiopathic nephrotic syndrome with alternate day steroids. Am J Med 62 (1): 60-70, 1977.
65. Miyata J, Takebayashi S, Taguchi T, Naito S, Harada T.: Evaluation and correlation of clinical and histological features of focal segmental glomerulosclerosis. Nephron 44 (2): 115-2, 1986.
66. Agarwal SK, Dash SC, Tiwari SC, Bhuyan UN.: Idiopathic adult focal segmental glomerulosclerosis: a clinicopathological study and response to steroid. Nephron 63 (2): 168-71, 1993.
67. Shiiki H, Nishino T, Uyama H y cols.: Clinical and morphological predictors of renal outcome in adult patients with focal and segmental glomerulosclerosis. Clin Nephrol 46 (6): 362-8, 1996.
68. Pokhariyal S, Gulati S, Prasad N y cols.: Duration of optimal therapy for idiopatic focal segmental glomerulosclerosis. J Nephrol 16: 691-696, 2003.
69. Meyrier A.: Nephrotic focal segmental glomerulosclerosis in 2004: an update. Nephrol Dial Trasplant 19: 2437-2444, 2004.
70. Korbet SM: Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 23 (2): 219-28, 2003.
71. Duncan N, Dhaygude A, Owen J y cols.: Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 19 (12): 3062-306, 2004.
72. Walker RG, Kincaid-Smith P.: The effect of treatment of corticosteroid-resistant idiopathic (primary) focal and segmental hyalinosis and sclerosis (focal glomerulosclerosis) with ciclosporin. Nephron 54 (2): 117-21, 1990.
73. Ponticelli C, Rizzoni G, Edefonti A y cols.: A randomized trial of cyclosporine in steroid-resistant idiopathic nephritic syndrome. Kidney Int 43 (6): 1377-84, 1993.
74. Cattran DC, Appel GB, Hebert LA y cols.: North America Nephrotic Syndrome Study Group. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney International 56 (6): 2220-2226, 1999.
75. Heering P, Braun N, Mullejans R y cols.: Collaborative Glomerulonephritis Study Group Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. American Journal of Kidney Diseases 43 (1): 10-18, 2004.
76. Maher ER, Sweny P, Chappel y cols.: Cyclosporine in the treatment of steroid-responsive and steroid resistant nephritic syndrome in adults. Nephrol Dial Trasplant 3: 728-732, 1998.
77. Lee HY, Kim HS, Kang CM y cols.: The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea. Clin Nephrol 43 (6): 375-81, 1995.
78. Meyrier A, Noel LH, Auriche P, Callard P.: Long-term renal tolerance of cyclosporine A treatment in adult idiopathic nephritic syndrome. Kidney Int 45 (5): 1446-1456, 1994.
79. Geary DF, Farine M, Thorner P, Baumal R.: Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal. Clin Nephrol 22 (3): 109-13, 1984.
80. Cade R, Mars D, Privette M y cols.: Effect of long term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic-syndrome resistant to corticosteroids. Arch Intern Med 146: 737-741, 1986.
81. Segarra A; Vila J; Pou L y cols. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Trasplant 17 (4): 655-62, 2002.
82. James A. Tumlin, Danlyn Miller y cols. A Prospective, Open-Label Trial of Sirolimus in the Treatment of Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 1: 109-116, 2006.
83. Quereda C, García López F, Álvarez-Rangel LE, Galeano C, Pascual J, Praga M.: Alternativas al tratamiento con ciclofosfamida en la Nefritis Lúpica. Nefrología 26 (Supl. 5): 43-52, 2006.
84. Cattran DC, Wang MM, Appel G y cols.: Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 62 (6): 405-11, 2004.
85. Day CJ, Cockwell P, Lipkin GW y cols.: Mycophenolate mofetil in the treatment of idiopatic nephritic syndrome. Nephrol Dial Trasplant 17: 2011-2013, 2002.
86. Usta M, Ersoy A, Dilek K, Ozdemir B, Yavuz M, Gullulu M, Yurtkuran M.: Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. J Intern Med 253 (3): 329-334, 2003.
87. Praga M, Hernández E, Montoyo C, Andrés A, Ruilope LM, Rodicio JL.: Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20: 240-248, 1992.
88. Stiles KP, Abbott KC, Welch PG, Yuan CM.: Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic. Clin Nephrol 56 (2): 89-95, 2001.
89. Gohh RY, Yango AF, Morrisey PE, Monaco AP, Gautam A, Sharma M, McCarthy ET, Savin VJ.: Preemptive plamapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 5 (12): 2907-2912, 2005.
90. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz CJ, Roza AM, Vincenti F, George V.: Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 68 (5): 635-641, 1999.
91. Torreta L, Perotti C, Costamagna L, Tarantino A, Salvaneschi L.: Usefulness of plasma exchange in recurrent nephrotic syndrome following renal transplant, Artif Organs 19 (1): 96-98, 1995.
92. Haas M, Godfrin Y, Oberbauer R, Yilmaz N, Borchhardt K, Regele H, Druml W, Derfler K, Mayer G.: Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 13: 2013-2016, 1998.